|
07 Jun 2019 |
Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus
|
|
04 Jun 2019 |
Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy
|
|
03 Jun 2019 |
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
|
|
02 Jun 2019 |
Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting
|
|
02 Jun 2019 |
Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting
|
|
31 May 2019 |
Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO
|
|
30 May 2019 |
Merz Pharma: Xeomin® (incobotulinumtoxinA) Receives European Approval for Treatment of Chronic Sialorrhea in Adults
|
|
29 May 2019 |
Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection
|
|
24 May 2019 |
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
|
|
23 May 2019 |
Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International Conference
|
|
18 May 2019 |
U.S. FDA Approves GATTEX® (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
|
|
14 May 2019 |
Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia
|
|
13 May 2019 |
TPX-100 Delays Pathological Changes of Bone in Osteoarthritis of the Knee
|
|
13 May 2019 |
FDA Approves Broadened Indication for XEOMIN® (IncobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients
|
|
12 May 2019 |
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
|
|
07 May 2019 |
European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older
|
|
07 May 2019 |
Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China
|
|
30 Apr 2019 |
BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites
|
|
29 Apr 2019 |
Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
|
|
28 Apr 2019 |
Evolus Receives Positive CHMP Opinion for Nuceiva™ in the European Union
|
|
28 Apr 2019 |
Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct® (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A
|
|
26 Apr 2019 |
Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes
|
|
24 Apr 2019 |
Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate
|
|
23 Apr 2019 |
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
|
|
12 Apr 2019 |
89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH
|
